Image de couverture de livre

Epigenetic changes shown to cause type 2 diabetes

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Iskandar Idris
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Diabetes, Obesity and Metabolism Now
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Fenofibrate shown to reduce progression of diabetic retinopathy
par: Iskandar Idris
Publié: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
par: Iskandar Idris
Publié: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
par: Iskandar Idris
Publié: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
par: Iskandar Idris
Publié: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
par: Iskandar Idris
Publié: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
par: Iskandar Idris
Publié: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
par: Iskandar Idris
Publié: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
par: Iskandar Idris
Publié: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
par: Iskandar Idris
Publié: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
par: Iskandar Idris
Publié: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
par: Iskandar Idris
Publié: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
par: Iskandar Idris
Publié: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
par: Iskandar Idris
Publié: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
par: Iskandar Idris
Publié: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
par: Iskandar Idris
Publié: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
par: Iskandar Idris
Publié: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
par: Iskandar Idris
Publié: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
par: Iskandar Idris
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
par: Iskandar Idris, et autres
Publié: (2025)

Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
par: Tamara Y. Milder, et autres
Publié: (2024)

Impact of time in tight range on all‐cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study
par: Jinghao Cai, et autres
Publié: (2025)

Visit‐to‐visit HbA1c variability, risk of all‐cause mortality and diabetes‐related vascular complications among adult individuals with type 2 diabetes mellitus
par: Moses Yidong Lim, et autres
Publié: (2026)

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
par: Djordje S. Popovic, et autres
Publié: (2024)

Estimating the risk of cardiovascular outcomes and all‐cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data
par: Ruth L. Coleman, et autres
Publié: (2025)

Longitudinal exposure to non‐ HDL ‐C and cardiovascular events, all‐cause mortality in type 2 diabetes: A post hoc analysis of the ACCORD trial
par: Yueyue Wang, et autres
Publié: (2026)

Cause‐specific death in adults with type 1 diabetes and type 2 diabetes: Insights from the UK Biobank
par: John W. Ostrominski, et autres
Publié: (2024)

Low serum 1,5‐anhydroglucitol is associated with increased risk of all‐cause and cardiovascular mortality in type 2 diabetes: A real‐world cohort study
par: Jiaying Ni, et autres
Publié: (2025)

Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus
par: Cheng Zu, et autres
Publié: (2024)

Effects of insulin‐induced hypoglycaemia on cardiac function in people with type 1 and type 2 diabetes and people without diabetes
par: Therese Wilbek Fabricius, et autres
Publié: (2025)

A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus
par: Carol Wysham, et autres
Publié: (2025)

Glycaemic treatment of newly diagnosed type 2 diabetes
par: Mayer B. Davidson
Publié: (2024)

Practical strategies to manage obesity in type 2 diabetes
par: Helena W. Rodbard, et autres
Publié: (2024)